SolastoTSE:6197 +0.18%59 ROE % is 2.90% as of Mar. 2026, which is 85% below its 10-year median of 19.22. GuruFocus rates TSE:6197 with a GF Score™ of 59/100 and a GF Value™ of 円563.54 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 625 Healthcare Providers & Services companies, Solasto ranks better than 77.76% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Solasto's annualized net income for the quarter that ended in Mar. 2026 was 円684 Mil. Solasto's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was 円23,550 Mil. Therefore, Solasto's annualized ROE % for the quarter that ended in Mar. 2026 was 2.90%.
The historical rank and industry rank for Solasto's ROE % or its related term are showing as below:
TSE:6197'
s ROE % Range Over the Past 10 Years
Min: 10.73 Med: 19.22 Max: 30.87
Current: 16.04
During the past 11 years, Solasto's highest ROE % was 30.87%. The lowest was 10.73%. And the median was 19.22%.
TSE:6197's ROE % is ranked better than 77.76% of 625
companies
in the Healthcare Providers & Services industry
Industry Median: 5.84
vs TSE:6197: 16.04
Solasto (TSE:6197) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Solasto ROE % Related Terms
Solasto ROE % Historical Data
* Premium members only.
The historical data trend for Solasto's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Solasto's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasto ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Solasto's ROE % distribution charts can be found below:
* The bar in red indicates where Solasto's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Solasto (TSE:6197) has a ROE % of 2.90% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Solasto and its competitors. This is 85% below median its historical median of 19.22. Over the past decade, Solasto's ROE % has ranged from 10.73 to 30.87. According to the industry distribution chart, Solasto ranks #139 out of 625 companies in the Healthcare Providers & Services industry, placing it in the top 22.2%.
Is Solasto's ROE % too high?
Solasto's current ROE % of 2.90% is 85% below median its 10-year median of 19.22. Over the past 10 years, this metric has ranged from a low of 10.73 to a high of 30.87. The Healthcare Providers & Services industry median ROE % is 5.84. Solasto's value of 2.90% is 50.3% below this industry median. Based on the distribution chart, Solasto ranks #139 out of 625 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Solasto has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasto's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Solasto ranks #139 out of 625 companies for ROE %. This places Solasto in the top 22% of its industry — outperforming the majority of peers. The industry median ROE % is 5.84. Solasto's value of 2.90% is 50.3% below this benchmark. Historically, Solasto's own ROE % has ranged from 10.73 to 30.87 over the past decade. While the company's 10-year median is 19.22 vs. the industry median of 5.84, Solasto has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.84, based on 625 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solasto's current ROE % of 2.90% is 50.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Solasto and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasto's current ROE % is 2.90%, which is 85% below median its own 10-year median of 19.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasto stock overvalued right now?
Based on GuruFocus' analysis, Solasto (TSE:6197) is currently considered Significantly Overvalued. The stock's GF Value™ is 円563.54, compared to a current price of 円1,111.00 — trading 97.1% above its estimated fair value. The current ROE % is 2.90%, which is 85% below median its 10-year median of 19.22 and 50.3% below the Healthcare Providers & Services industry median of 5.84. Solasto's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Solasto (TSE:6197), the current ROE % is 2.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasto (TSE:6197) Overvalued in 2026?
Based on GuruFocus' analysis, Solasto stock appears to be overvalued.
The current stock price of 円1,111.00 is trading 97.1% above its estimated GF Value™ of 円563.54.
GuruFocus considers Solasto to be Significantly Overvalued.
Key valuation signals for TSE:6197:
ROE %: 2.90% (85% below median its 10-year median of 19.22)
GF Value™: 円563.54 vs. price of 円1,111.00 (97.1% above fair value)
Industry Position: 50.3% below the Healthcare Providers & Services median (#139 of 625)
No single metric tells the full story. See the TSE:6197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6197 has been successfully added to your 
